NCT05241262View on ClinicalTrials.gov

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Mitochondrial Disease
Interventions
DRUG

N-Acetylcysteine

1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Michio Hirano, MD

OTHER